Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

258
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
258
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

335
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
335
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

346
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
346
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

304
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
304
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

762
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
762
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

746
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
746

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Serum and Urinary Metabolomics Reflect the Early Stages of De Novo Metabolic Syndrome After Liver Transplant: A 2-Center Longitudinal Study.

Clinical and translational gastroenterology·2026
Same author

Impact of liver cirrhosis etiology on results of diagnostic tests for minimal hepatic encephalopathy.

Scientific reports·2026
Same author

Loss, amplification or mistiming of the daily rhythms of metabolic markers in patients with cirrhosis.

JHEP reports : innovation in hepatology·2026
Same author

Disturbed regulation of immunothrombosis in cerebral ischemia associated with SARS-CoV-2 infection.

Frontiers in immunology·2026
Same author

Aminoglycosides, vancomycin, and metronidazole for people with cirrhosis and hepatic encephalopathy.

The Cochrane database of systematic reviews·2026
Same author

Serum and Urinary Metabolomics Reflect the Early Stages of De Novo Metabolic Syndrome After Liver Transplant: A 2-Center Longitudinal Study.

Clinical and translational gastroenterology·2026
Same journal

Transthyretin at the crossroads of neurodegeneration: a silent guardian in Parkinson's disease.

Metabolic brain disease·2026
Same journal

Genetic and structural characterisation of alzheimer's disease associated variants in an Eastern Indian cohort.

Metabolic brain disease·2026
Same journal

Sex-specific gut microbiota and metabolite signatures in Parkinson's disease: implications for personalized therapeutics.

Metabolic brain disease·2026
Same journal

Genetic mutations and synaptic dysfunctions in social interaction disorders: insights from invertebrate models to humans.

Metabolic brain disease·2026
Same journal

Crocin alleviates "short-term" Cadmium-induced brain and lung toxicities: investigation of key neuropeptides GLP-1 and spexin as biomarkers.

Metabolic brain disease·2026
Same journal

Electroacupuncture-modulated DHCR24 facilitates spinal cord injury recovery by attenuating apoptosis and neuroinflammation via the Wnt signaling pathway.

Metabolic brain disease·2026
See all related articles

Related Experiment Video

Updated: Apr 2, 2026

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy
10:30

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy

Published on: May 16, 2015

20.4K

Qualifying and quantifying minimal hepatic encephalopathy.

Marsha Y Morgan1, Piero Amodio2, Nicola A Cook3

  • 1UCL Institute for Liver & Digestive Health, Division of Medicine, Royal Free Campus, University College London, Rowland Hill Street, London, NW32PF, UK. marsha.morgan@ucl.ac.uk.

Metabolic Brain Disease
|September 29, 2015
PubMed
Summary
This summary is machine-generated.

Diagnosing minimal hepatic encephalopathy (MHE) in cirrhosis patients is crucial for improving quality of life. Current guidelines recommend the Portal Systemic Hepatic Encephalopathy Score (PHES) alongside other validated tests for accurate MHE diagnosis.

Keywords:
DiagnosisMinimal hepatic encephalopathyNeurophysiologyNeuropsychometry

More Related Videos

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury
07:27

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury

Published on: October 21, 2017

12.5K
Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

12.2K

Related Experiment Videos

Last Updated: Apr 2, 2026

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy
10:30

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy

Published on: May 16, 2015

20.4K
The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury
07:27

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury

Published on: October 21, 2017

12.5K
Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

12.2K

Area of Science:

  • Hepatology
  • Neuropsychiatry
  • Diagnostic Medicine

Background:

  • Minimal hepatic encephalopathy (MHE) affects cirrhosis patients without overt clinical signs, impacting cognitive function.
  • Diagnosis is challenging due to the absence of clear clinical indicators, necessitating sensitive testing.
  • Existing diagnostic methods vary in accessibility and validation.

Purpose of the Study:

  • To review current diagnostic tools for minimal hepatic encephalopathy in cirrhosis patients.
  • To evaluate the efficacy and limitations of various psychometric and neurophysiological tests.
  • To inform the development of standardized diagnostic algorithms for MHE.

Main Methods:

  • Review of psychometric tests, including the widely used Portal Systemic Hepatic Encephalopathy Score (PHES).
  • Evaluation of neurophysiological methods like electroencephalogram (EEG) and emerging techniques.
  • Assessment of other validated tools such as Critical Flicker Frequency and reaction time tests.

Main Results:

  • PHES is a well-validated tool, with normative data available internationally.
  • EEG performance is analysis-dependent; spectral analysis and portable headsets show promise.
  • Multiple alternative tests exist, each with unique strengths and weaknesses, as noted in recent AASLD/EASL guidelines.

Conclusions:

  • Current guidelines suggest combining PHES with an alternative validated test or EEG for MHE diagnosis.
  • Effective diagnosis of MHE is essential for treatment, improving patient well-being and outcomes.
  • Standardized diagnostic algorithms and collaborative efforts are needed for widespread MHE detection.